Log In
BCIQ
Print this Print this
 

HBV-SLP (ISA204) (formerly ISA-HBV)

  Manage Alerts
Collapse Summary General Information
Company ISA Pharmaceuticals B.V.
DescriptionSynthetic long peptide (SLP) immunotherapeutic derived from hepatitis B antigens with crystallographic structure modeling of the ligand receptor interaction
Molecular Target Toll-like receptor 1 (TLR1) ; Toll-like receptor 2 (TLR2)
Mechanism of ActionImmunotherapy
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPreclinical
Standard IndicationHepatitis B virus (HBV)
Indication DetailsTreat liver diseases caused by hepatitis B virus (HBV) infections
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today